Adalimumab in Rheumatoid Arthritis. An Investigation of Wholebody MRI, Conventional MRI, CT and Circulating Biomarkers

Inclusion Criteria: * Age \> 18 years old and \< 85 years old * RA in accordance with American College of Rheumatology 1987 criteria * Moderate or highly active RA defined as DAS28 \> 3,2 (CRP based) * Clinical indication for TNF-α inhibitor treatment by the treating physician * No contraindications for TNF-α inhibitor treatment * No contraindications for MRI * Serum creatinine in normal range * Sufficient contraception for fertile women * Capable of giving informed consent * Capable of complying with the examination program of the protocol Exclusion Criteria: * Other DMARDs than MTX from less than 4 weeks before inclusion and throughout the study period * Cyclophosphamide, Chlorambucil or other alkylating agents from less than 4 weeks before inclusion and throughout the study period * Intramuscular or intravenous injection of glucocorticoid from less than 4 weeks before inclusion and throughout the study period * Pregnancy wish, pregnancy or breast-feeding * Contraindications for TNF-α inhibitor treatment * Contraindications for MRI * Known recent drug or alcohol abuse * Failure to provide written consent * Incapable of complying with the examination program for physical or mental reasons